Suggested Readings
Final results from the randomized phase III ASCENT clinical trial in metastatic triple-negative breast cancer and association of outcomes by human epidermal growth factor receptor 2 and trophoblast cell surface antigen 2 expression.
Bardia A, et al. J Clin Oncol. 2024;42(15):1738-1744.
Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer.
Hurvitz SA, et al. NPJ Breast Cancer. 2024;10(1):33.
Sacituzumab govitecan in hormone receptor–positive/human epidermal growth factor receptor 2–negative metastatic breast cancer.
Rugo HS, et al. J Clin Oncol. 2022;40(29):3365-3376.
Incidence of interstitial lung disease and cardiotoxicity with trastuzumab deruxtecan in breast cancer patients: a systematic review and single-arm meta-analysis.
Soares LR, et al. ESMO open. 2023;8(4):101613.
Targeting HER2-low in metastatic breast cancer: an evolving treatment paradigm.
Yang C, et al. Ther Adv Med Oncol. 2023;15: 17588359231175440.
Linked Resources
Guidelines
NCCN Guidelines®: Breast Cancer, version 6.2024
Gradishar WJ, et al. J Natl Compr Canc Netw. 2024.
Clinician and Patient Resources
National Breast Cancer Foundation, Inc.
Susan G. Komen Breast Cancer Foundation
European Society of Medical Oncology Congress 2024
Related activities
![](https://exchangecme-public-live.s3.amazonaws.com/files/upload/images/activities/6750e5b680707.png)
![](https://exchangecme-public-live.s3.amazonaws.com/files/upload/images/ext-images/65147d8297293.png)
![](/themes/desktop2/images/NEW-tag2x.png)
Webcast
0.75 AMA PRA
Backwards & Forwards: ADC Therapy for mBC
Everything You Need to Know About ADCs for the Treatment of mBC
Faculty: | Joyce A. O’Shaughnessy, MD |
Release: | 12/16/2024 |
Expiration: | 12/16/2025 |